Genexine Current Valuation vs. Price To Sales
| 095700 Stock | KRW 5,880 230.00 4.07% |
For Genexine profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Genexine to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Genexine utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Genexine's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Genexine over time as well as its relative position and ranking within its peers.
Genexine |
Genexine Price To Sales vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Genexine's current stock value. Our valuation model uses many indicators to compare Genexine value to that of its competitors to determine the firm's financial worth. Genexine is the top company in current valuation category among its peers. It also is number one stock in price to sales category among its peers . The ratio of Current Valuation to Price To Sales for Genexine is about 197,573,502,929 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Genexine by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Genexine's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Genexine Current Valuation vs. Competition
Genexine is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 4 Trillion. Genexine totals roughly 2.14 Trillion in current valuation claiming about 54% of equities under Health Care industry.
Genexine Price To Sales vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Genexine |
| = | 2.14 T |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Genexine |
| = | 10.84 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Genexine Price To Sales Comparison
Genexine is currently under evaluation in price to sales category among its peers.
Genexine Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Genexine, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Genexine will eventually generate negative long term returns. The profitability progress is the general direction of Genexine's change in net profit over the period of time. It can combine multiple indicators of Genexine, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea. Genexine is traded on Korean Securities Dealers Automated Quotations in South Korea.
Genexine Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Genexine. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Genexine position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Genexine's important profitability drivers and their relationship over time.
Use Genexine in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Genexine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genexine will appreciate offsetting losses from the drop in the long position's value.Genexine Pair Trading
Genexine Pair Trading Analysis
The ability to find closely correlated positions to Genexine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genexine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genexine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genexine to buy it.
The correlation of Genexine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genexine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genexine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genexine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Genexine position
In addition to having Genexine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Buywrite ETFs Thematic Idea Now
Buywrite ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Buywrite ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Buywrite ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Genexine Stock
To fully project Genexine's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Genexine at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Genexine's income statement, its balance sheet, and the statement of cash flows.